5-HT锛�5-Hydroxytryptamine锛�5-缇ヨ壊鑳猴級绁炵稉(j墨ng)閬炶唱涓昏鍒嗗竷浜庢澗鏋滈珨鍜屼笅涓樿叇锛屽彲鍙冭垏椋熸銆侀珨婧绡�(ji茅)锛屾儏绶�锛屽績琛�绠″姛鑳�锛屽収鍒嗘硨鍜屾姂閮佺瓑鐢熺悊鍔熻兘鐨勮绡�(ji茅)銆�5-HT閫氶亷婵�鍕曚笉鍚岀殑5-HT鍙楅珨锛屽彲鍏锋湁涓嶅悓钘ョ悊浣滅敤锛屽洜姝わ紝5-HT鍙楅珨鎷姉鍔戞垚鐐鸿棩鐗╄ō瑷堢殑鐮旂┒鐔遍粸[1][2]銆傜櫨闈堝▉浣滅偤灏堟キ(y猫)瑭﹀姂渚涙噳鍟嗭紝鎻愪緵澶氱ó5-HT鍙楅珨鎷姉鍔�锛岀偤鎮ㄧ殑绉戠爺鍔╁姏鍔犳补锛�
鈼� 璩噺绌�(w臎n)瀹�锛屾�у児姣旈珮
鈼� 鐝�(xi脿n)璨ㄤ緵鎳�锛岀櫦(f膩)璨ㄥ強鏅�
|
鐢㈠搧绶ㄨ櫉
|
涓嫳鏂囧悕绋�
|
CAS
|
瑕�(gu墨)鏍�
|
|
384285
|
Granisetron hydrochloride, 98%, a serotonin 5-HT3 receptor antagonist
楣介吀鏍兼媺鍙哥搳, 98%, 5-HT3鍙楅珨鎷姉鍔�
|
107007-99-8
|
200 mg
1 g
|
|
283801
|
Ketanserin, 99%, a specific 5-HT2A serotonin receptor antagonist
鍑变粬鑹叉灄, 99%, 鐗圭暟鎬х殑5-HT2A 5-缇ヨ壊鑳哄彈楂旀嫯鎶楀姂
|
74050-98-9
|
250 mg
1 g
|
|
185928
|
Lamotrigine, 98%, Novel anticonvulsant drug for inhibition of 5-HT
鎷夎帿涓夊棯, 98%, 鎶戝埗5-缇ヨ壊鑳�(5-HT)鍚告敹
|
84057-84-1
|
1 g
5 g
|
|
574335
|
Mirtazapine, 99%, 5-HT Receptor
绫崇埦濉旀墡骞�, 99%, 5-HT鍙楅珨鎶戝埗鍔�
|
85650-52-8
|
100 mg
|
|
496697
|
Olanzapine, 99%, High affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist
濂ф爱骞�, 99%, 5-HT2鍜�D2鍙楅珨楂樿Κ鍜屾�ф嫯鎶楀姂
|
132539-06-1
|
1 g
5 g
|
|
977215
|
Paliperidone, 99%, potent D2 and 5-HT2A antagonist
甯曟綐绔嬮叜, 99%, 楂樻晥D2鍜�5HT2A鎷姉鍔�
|
144598-75-4
|
10 mg
50 mg
|
|
144809
|
Sumatriptan succinate, 98%, 5-HT1 receptor agonist
鐞ョ弨閰歌垝棣洸鏅潶, 98%, 5-HT1 鍙楅珨婵�鍕曞姂
|
103628-48-4
|
100 mg
500 mg
|
|
522188
|
Tropisetron monohydrochloride, 99%, 5-HT3 receptor antagonist and α7-nicotinic receptor agonist
楣介吀鎵樼兎鍙哥搳, 99%, 5-HT3鍙楅珨鎷姉鍔戝拰α7-鐓欏牽鍙楅珨婵�鍕曞姂
|
105826-92-4
|
1 g
5 g
|
|
186095
|
Ziprasidone hydrochloride monohydrate, 99%, a novel and potent dopamine and serotonin (5-HT) receptor antagonist
榻婃媺瑗块叜楣介吀楣戒竴姘村悎鐗�, 99%, 鏈夋晥鐨�dopamine 鍜� serotonin (5-HT) receptor鐨勬嫯鎶楀姂
|
138982-67-9
|
250 mg
1 g
|
.png)
.png)
Figure1 Figure2
Figure1: Structure of Lamotrigine (185928)[1]
Figure2: Interactions of Lamotrigine(185928) with the binding pocket (subdomain IB)[1]
References
[1] Poureshghi F, Ghandforoushan P, Safarnejad A, et al. Interaction of an antiepileptic drug, lamotrigine with human serum albumin (HSA): Application of spectroscopic techniques and molecular modeling methods[J]. Journal of Photochemistry and Photobiology B: Biology, 2017, 166: 187-192.
[2]Yatham L N, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial[J]. Molecular psychiatry, 2016, 21(8): 1050-1056.
|
鐢㈠搧绶ㄨ櫉
|
涓嫳鏂囧悕绋�
|
CAS
|
鍖呰瑕�(gu墨)鏍�
|
|
163651
|
(+)-Bicuculline, 99.5%, GABAA antagonist
(+)-鑽峰寘鐗′腹鍫�, 99.5%, GABAA 鎷姉鍔�
|
485-49-4
|
25 mg
100 mg
|
|
240627
|
Candesartan cilexetil, 98%, ATR antagonist
鍧庡湴娌欏潶閰�, 98%, ATR 鎷姉鍔�
|
145040-37-5
|
50 mg
100 mg
500 mg
|
|
410760
|
Cyproterone acetate, 98%, an androgen receptor (AR) antagonist
鐠�(hu谩n)涓欏瓡閰唻閰搁菇, 98%, 涓�绋泟婵�绱犲彈楂旀嫯鎶楀姂
|
427-51-0
|
50 mg
250 mg
1 g
|
|
195685
|
Leuprorelin acetate, 98%, an agonist at pituitary GnRH receptors
閱嬮吀浜笝鐟炴灄, 98%, 涓�绋瀭楂斾績鎬ц吅婵�绱犲彈楂旀姂鍒跺姂
|
74381-53-6
|
5 mg
25 mg
|
|
408413
|
Tropicamide, 99%, potent selective M4 antagonist
鎵樺搧閰拌兒, 99%, 鏈夋晥閬告搰鎬�M4鎷姉鍔�
|
1508-75-4
|
10 g
|
鈻� 鐩搁棞鐢㈠搧锛�